We're developing nanovaccines and nanotherapeutics

About us

Our universal influenza nanovaccine will be effective against more strains of flu

Respiratory infections research

Nanovaccines can prevent parasitic diseases such as malaria and filariasis

Antimicrobial Resistance research

Nanotherapeutics can treat Parkinson's, Alzheimer's, and traumatic brain injury

Neural disorders

We're researching tumor-specific targets for cancer diagnostics and nanotherapeutics

Cancer research

Nanotechnologies can help optimize aging with improved biosensors and vaccine delivery

Aging research

Researching veterinary diseases helps design nanovaccines for similar diseases in humans

Animal health research
ABOUT US ABOUT US

Consortium of experts

The Nanovaccine Institute is a consortium of 79 researchers at 24 universities, research institutes, national laboratories, and companies, founded and coordinated by Iowa State University.

Interdisciplinary research

Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, antimicrobial resistance, cancer, aging, and animal health. Our vision is that nanovaccines and nanotherapeutics will revolutionize how we prevent and treat disease.

Revolutionizing how we
6 6
Focus Areas
79 79
Researchers
24 24
Institutions
prevent and treat disease

NANOVACCINE INSTITUTE RESEARCHER PROFILE

Dr. Surya Mallapragada, Iowa State University